BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company has submitted its Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Natpara® (recombinant human parathyroid hormone 1-84, rhPTH(1-84)). Natpara is a bioengineered replacement for endogenous parathyroid hormone (PTH) that NPS has developed for the treatment of hypoparathyroidism, a rare endocrine disorder in which the body produces insufficient levels of parathyroid hormone, a principal regulatory of the body’s mineral homeostasis.
Help employers find you! Check out all the jobs and post your resume.
